Pain, Acute
Conditions
Brief summary
This study aims to evaluate the analgesic effect and the safety of 4 doses of STR-324 administered as an infusion, with or without initial bolus, to patients suffering from post-operative pain. The sensitivity of the pain model used in the trial will be evaluated with a standard group treated with morphine under the usual care conditions.
Detailed description
The first step (single-blind standard group) aims to verify the sensitivity of the study pain model in the proposed surgery to confirm the validity of the surgery according to their pain and enrolment rate. 12 patients are planned to be enrolled. The second step (dose-finding study) is a randomized, double-blind, parallel groups, controlled clinical trial involving a total of 106 patients divided into two groups in which patients will be randomized between STR-324 and morphine HCl: * Group 1: Titration initiated with a bolus * Group 2: Titration without initial bolus.
Interventions
DRUGMorphine
Repeated bolus according to pain score
DRUGMorphine HCl
Infusion of morphine HCl solution for intravenous administration
DRUGSTR-324
Infusion of solution for intravenous administration
Sponsors
Alaxia SAS
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
Step 1 of the study is single blinded for participants only.
Eligibility
Sex/Gender
ALL
Age
18 Years to 64 Years
Healthy volunteers
No
Inclusion criteria
Selection criteria: 1. Patient aged ≥18 to \<65 years old, at screening; 2. Having signed an informed consent prior to any study-related procedure; 3. Patients planned to undergo a major laparoscopic abdominal or pelvic surgery; 4. Surgery to be performed without local or regional anaesthesia nor infiltration; 5. Body mass index (BMI) between 18 and 30 kg/m² inclusive at screening, and with a minimum weight of 50 kg; 6. Women of childbearing potential must agree to use at least one effective contraceptive method upon enrolment and for 1 cycle following the last dose of the investigational product. Inclusion Criteria: The criteria for definitive enrolment must be checked in the Post-Anaesthesia Care Unit (PACU) at the inclusion visit: 1. NRS-measured pain intensity ranging from 4 to 8 inclusive at baseline PACU measurement; 2. With a sedation score ≤ S1 (awake or intermittently sleepy) at the time of pain assessment.
Exclusion criteria
1. Patient contra-indicated for morphine administration; 2. Unstable or poorly controlled psychiatric condition (e.g., untreated PTSD, major anxiety, or depression). Subjects who take stable doses (same dose \>30 days) of antidepressants and/or anti-anxiety drugs may be included; 3. Women who are pregnant or breastfeeding; 4. History of alcohol, opiate or other drug abuse. 5. Evidence of any active or chronic disease or condition that could interfere with, or for which the treatment might interfere with the conduct of the study, or that would pose an unacceptable risk to the subject in the opinion of the investigator. Minor deviations of values from the normal range may be accepted, if judged by the Investigator to have no clinical relevance; 6. Clinically significant abnormalities, as judged by the investigator, in laboratory test results; 7. Participation in an investigational drug or device study within 1 month prior to dosing.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Qualitative Change of Pain Intensity | On and/or after study drug, with fixed timepoints at 5, 10, 15, 20, 30, 45, 60, 75, 90, 105 and 120 minutes. If re-titration is required/performed, additional 5-minutes interval timepoints shall be added. | Pain Intensity will be assessed by a Numerical Rating Scale (NRS) before and during analgesic infusion. Change of Pain Intensity assessed by the Numerical Rating Scale (NRS) after initiation of the post-op analgesia and before switch to standard treatment. The following parameter will be assessed: \- Qualitative: a decrease of 2 units minimum from baseline and/or achievement of a pain score ≤ 3 is considered successful, responder=Yes. |
| Quantitative Change of Pain Intensity | On and/or after study drug, with fixed timepoints at 5, 10, 15, 20, 30, 45, 60, 75, 90, 105 and 120 minutes. If re-titration is required/performed, additional 5-minutes interval timepoints shall be added. | Pain Intensity will be assessed by a Numerical Rating Scale (NRS) before and during analgesic infusion. Change of Pain Intensity assessed by the Numerical Rating Scale (NRS) after initiation of the post-op analgesia and before switch to standard treatment. The following parameter will be assessed: \- Quantitative: maximum value of the pain score difference versus baseline. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adverse events collection | AEs collected directly after surgery until at least 30 days after the day of surgery. | Any untoward medical occurrence in a patient or a clinical investigation subject, which does not necessarily have a causal relationship with the study treatment. |
Countries
Netherlands
Contacts
Primary ContactAnnie-Claude Benichou
Backup ContactPascale Vermare
Outcome results
None listed